JPMorgan Leads, Jefferies Joins $4.25 Billion Financing for Lantheus Deal

Lantheus (LNTH) reported receiving a second request from the FTC regarding its $8B sale to Curium. Both companies were asked for additional information by the FTC on Wednesday.

Lantheus and Curium received FTC Second Requests on October 21, extending the HSR waiting period. The companies expect to respond promptly and continue to anticipate closing the merger in the first half of 2027, subject to regulatory approvals.

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US Holdings LLC, a Delaw

Lantheus (NASDAQ: LNTH) announced CMS granted Transitional Pass-Through payment status for PYLARIFY® TruVu (piflufolastat F 18), effective October 1, 2026. This designation enables separate reimbursement in hospital outpatient settings, supporting access to the diagnostic radiopharmaceutical for Medicare beneficiaries. PYLARIFY TruVu is a new formulation of Lantheus’ PSMA-targeted PET imaging agent for prostate cancer, with a permanent HCPCS code assigned for billing and reimbursement.

Polaris Capital's Q2 2026 investor letter highlights Lantheus Holdings (LNTH) as a top performer. The company's stock rose due to strong earnings, FDA approval of PYLARIFY TruVu, and a potential $7B takeover bid from Curium Pharma. LNTH's shares are up 92.62% over 52 weeks, closing at $100.28 on September 22, 2026, with a market cap of $6.55B.

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US Holdings LLC, a Delaw